Hypothesizing an intestinal barrier impairment as a common pathophysiological substrate of both Non Celiac Wheat Sensitivity (NCWS) and Metabolic Dysfunction-Associated Steatotic Liver Disease (MAFLD), in a retrospective cohort study (data not yet published), demographic, clinical, laboratory and histology data of NCWS patients at the time of diagnosis, were analyzed and compared to control subjects with Irritable Bowel Syndrome/Functional Dyspepsia (IBS/FD) and freshly diagnosed Celiac Disease (CeD). NCWS diagnosis was performed by a neither you nor the study doctors know who gets the real treatment compared with a dummy treatment wheat challenge.
Official registry: https://clinicaltrials.gov/study/NCT07750535 · University of Palermo · enrollment listed as 250
This is an observational study. You are not assigned a new experimental drug. Researchers measure what already happens in your care or in daily life.
Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
This listing is observational (StudyType). The registry does not assign a new experimental drug as the study intervention.
They plan to enroll about 250 people at 2 sites. Taking part typically means study visits and measurements plus check-ins.
Prevalence and Risk Factors of Liver Steatosis and Fibrosis in Non-Celiac Wheat Sensitivity Patients: a Prospective Study
Interventions: Prevalence and severity of liver steatosis and fibrosis,
Primary outcome (registry wording): Prevalence and severity of liver steatosis and fibrosis by Ultrasound examination
Antonio Carroccio, MD
Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.
Aim: More insight in pathogenesis of IBS and IBD. Samples are collected in context of an European research project.
NCT02421705 · Official ClinicalTrials.gov record · KU Leuven
Gastrointestinal (GI) infection with Campylobacter causes inflammation in the bowel and can change bacteria in the gut. Certain individuals with Campylobacter infection are also known to develop chronic bowel problems such as Irritable Bowel Syndrome (IBS).
NCT03223077 · Official ClinicalTrials.gov record · Mayo Clinic
This study will assess the how well it works of two active treatments with TEA and a chemical neuromodulator (escitalopram aka Lexapro) versus a sham comparator or control group on abdominal pain.
NCT05519683 · Official ClinicalTrials.gov record · University of Michigan
The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.
Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.
How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary